CN Patent

CN101410119A — 新颖的依前列醇制剂及其制备方法

Assigned to Actelion Pharmaceuticals Ltd · Expires 2009-04-15 · 17y expired

What this patent protects

本发明涉及稳定的依前列醇组合物，该组合物可以与商购Ⅳ流体组合并且可以在约15－30℃的环境条件下以其重新配制和/或稀释的形式给药24小时以上。该组合物优选包含：(a)依前列醇或其盐；(b)碱化试剂；和(c)碱，使得在重新配制或为溶液形式时，溶液具有pH＞11。还公开了制备冻干组合物的方法。

USPTO Abstract

本发明涉及稳定的依前列醇组合物，该组合物可以与商购Ⅳ流体组合并且可以在约15－30℃的环境条件下以其重新配制和/或稀释的形式给药24小时以上。该组合物优选包含：(a)依前列醇或其盐；(b)碱化试剂；和(c)碱，使得在重新配制或为溶液形式时，溶液具有pH＞11。还公开了制备冻干组合物的方法。

Drugs covered by this patent

epoprostenol-sodium (EPOPROSTENOL SODIUM)

Patent Metadata

Patent number: CN101410119A
Jurisdiction: CN
Classification: —
Expires: 2009-04-15
Drug substance claim: No
Drug product claim: No
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.